Deborah E Collyar
Overview
Explore the profile of Deborah E Collyar including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
819
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Peppercorn J, Shapira I, Deshields T, Kroetz D, Friedman P, Spears P, et al.
Cancer
. 2012 Mar;
118(20):5060-8.
PMID: 22415847
Background: The rapid pace of genetics research, coupled with evolving standards for informed consent, can create ethical challenges regarding future use of tissue or information from completed clinical trials. The...
12.
Katz M, Archer L, Peppercorn J, Kereakoglow S, Collyar D, Burstein H, et al.
Cancer
. 2012 Mar;
118(19):4801-5.
PMID: 22392584
Background: Patient advocates are increasingly involved in cooperative group trials, single-institution cancer programs, and peer-review of research applications. The purpose of this study was to evaluate the role and value...
13.
Collyar D
J Natl Cancer Inst Monogr
. 2011 Jun;
2011(42):41-2.
PMID: 21672895
This commentary includes the public- and patient-oriented perspective on research biospecimens and the National Cancer Institute's cancer HUman Biobank (caHUB) project. Definitions of biospecimens and the importance to the research...
14.
Demmy T, Yasko J, Collyar D, Katz M, Krasnov C, Borwhat M, et al.
J Clin Oncol
. 2004 Jul;
22(15):2997-3002.
PMID: 15284251
No abstract available.
15.
Chlebowski R, Col N, Winer E, Collyar D, Cummings S, Vogel 3rd V, et al.
J Clin Oncol
. 2002 Aug;
20(15):3328-43.
PMID: 12149307
Objective: To update an evidence-based technology assessment of chemoprevention strategies for breast cancer risk reduction. POTENTIAL INTERVENTIONS: Tamoxifen, raloxifene, aromatase inhibition, and fenretinide. Outcomes: Outcomes of interest include breast cancer...
16.
Collyar D
Breast J
. 2001 May;
6(5):310-314.
PMID: 11348388
Clinical trials are essential in developing new treatments, care, and prevention for people with cancer. Unfortunately U.S. accrual rates for adult cancers are approximately 2-3%, partly due to the way...